Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (50.0%)
N/A1 (50.0%)

Trials by Status

unknown133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
unknownnot_applicable

Stressors and Recovery Regulation on the Super-compensation Effect

NCT06295016
terminated

Team Approach to Polypharmacy Reduction to Improve Mobility Long-Term Care

NCT03202264
terminatedphase_4

REMission INDuction in Very Early Rheumatoid Arthritis

NCT02935387

Clinical Trials (3)

Showing 3 of 3 trials
NCT06295016Not Applicable

Stressors and Recovery Regulation on the Super-compensation Effect

Unknown
NCT03202264

Team Approach to Polypharmacy Reduction to Improve Mobility Long-Term Care

Terminated
NCT02935387Phase 4

REMission INDuction in Very Early Rheumatoid Arthritis

Terminated

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3